United Stock Story

All Stories . Risk . 
Raphi Shpitalnik .  Story
UTHR
 Stock
  

USD 224.97  1.53  0.68%   

By Raphi Shpitalnik
Macroaxis Story
Lets try to sum up the odds of United Therapeutic to fully recover from the latest fall as its shares went up 3.72%. United Therapeutic current daily volatility is 2.45 percent, with a beta of 0.54 and an alpha of -0.11 over DOW. While some baby boomers are getting worried about saving accounts, it is reasonable to sum up United Therapeutic. What exactly are United Therapeutic shareholders getting in June?
Published over three months ago
View all stories for United Therapeutic | View All Stories

Chances of United Therapeutic to fall after the volatility advances

The company conducts business under Healthcare sector and is part of Biotechnology industry.
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. United Therapeutic has an asset utilization ratio of 77.37 percent. This connotes that the company is making $0.77 for each dollar of assets. An increasing asset utilization means that United Therapeutic is more efficient with each dollar of assets it utilizes for everyday operations.
Investing in United Therapeutic, just like investing in any other equity instrument, is characterized by a strong risk-return correlation. High risks mean high returns and low risk means lower expected returns. Risk management is the act of identifying and assessing the potential risk and developing strategies to minimize these risks and earn maximum possible profits while holding United Therapeutic along with other instruments in the same portfolio. Using conventional technical analysis and fundamental analysis to select individual securities into a portfolio complements risk management and adds value to overall investors' investing strategies.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of United Therapeutic's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of United Therapeutic in the context of predictive analytics.
Hype
Prediction
Details
Intrinsic
Valuation
Details
Naive
Forecast
Details
9 Analysts
Consensus
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as United Therapeutic. Your research has to be compared to or analyzed against United Therapeutic's peers to derive any actionable benefits. When done correctly, United Therapeutic's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in United Therapeutic.

How important is United Therapeutic's Liquidity

United Therapeutic financial leverage refers to using borrowed capital as a funding source to finance United Therapeutic ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. United Therapeutic financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between United Therapeutic's total debt and its cash.

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions.
It is good to see analyst projects for United Therapeutic, but it might be worth checking our own buy vs. sell analysis

What is the case for United Therapeutic Investors

United Therapeutic owns Efficiency Ratio (i.e., Sharpe Ratio) of -0.029, which indicates the firm had -0.029% of return per unit of risk over the last 3 months. Macroaxis standpoint towards measuring the risk of any stock is to look at both systematic and unsystematic factors of the business, including all available market data and technical indicators. United Therapeutic exposes twenty-eight different technical indicators, which can help you to evaluate volatility that cannot be diversified away. Please be advised to validate United Therapeutic risk adjusted performance of (0.07), and Coefficient Of Variation of (1,678) to confirm the risk estimate we provide.
REGN
BNTX
CMXHF
VRTX
MRNA
REGN
0.370.740.890.39
REGN
BNTX
0.370.260.270.88
BNTX
CMXHF
0.740.260.540.41
CMXHF
VRTX
0.890.270.540.19
VRTX
MRNA
0.390.880.410.19
MRNA
REGN
BNTX
CMXHF
VRTX
MRNA
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio

Over 3 percent spike for United Therapeutic. What does it mean for retail investors?

Latest Information Ratio is up to -0.03. Price may fall again. United Therapeutic exhibits very low volatility with skewness of -2.57 and kurtosis of 14.17. However, we advise investors to further study United Therapeutic technical indicators to make sure all market info is available and is reliable. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure United Therapeutic's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact United Therapeutic's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

United Therapeutic Implied Volatility

United Therapeutic's implied volatility exposes the market's sentiment of United Therapeutic stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if United Therapeutic's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that United Therapeutic stock will not fluctuate a lot when United Therapeutic's options are near their expiration.

Our Conclusion on United Therapeutic

While some firms in the biotechnology industry are either recovering or due for a correction, United may not be as strong as the others in terms of longer-term growth potentials. While some short-term oriented retail investors may not share our view, we believe it may be a good time to buy new shares of United.

Editorial Staff

Raphi Shpitalnik is a Junior Member of Macroaxis Editorial Board. Raphael is a young entrepreneur who joined Macroaxis on a part-time base at the beginning of the pandemic and eventually acquired a real test for investing and fintech. He likes to analyze different equity instruments across a wide range of industries, focusing primarily on consumer products, sports, fintech, cannabis, and AI. View Profile
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of United Therapeutic. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2022 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY